On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
REGULATORY
LDP Going into Tax Reform Debate for FY2021
The ruling Liberal Democratic Party’s (LDP) Tax Commission held a general assembly meeting on November 19 to kick off its tax reform debate for FY2021 beginning next April. It will now begin collecting opinions from each LDP committee about their…
To read the full story
REGULATORY
- MHLW Plans 4-Week Follow-Up Study on Early COVID-19 Vaccine Recipients
January 21, 2021
- Kobayashi Kako Submits Report on Drug Mix-Up, Could Face Administrative Penalty in 1st Half of February
January 21, 2021
- Japan, Pfizer Finalize COVID-19 Vaccine Deal, Agree on Supply of 144 Million Doses
January 21, 2021
- Japan Weighs Pfizer COVID-19 Vaccine Rollout for Age 16 and Up
January 20, 2021
- LDP to Set Up Project Team for COVID-19 Vaccine Rollout, Submits Roadmap to PM
January 20, 2021
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…